

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

CFPAC-1

RRID:CVCL_1119

Type: Cell Line

Proper Citation

RRID:CVCL_1119

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1119

Proper Citation: RRID:CVCL_1119

Description: Cell line CFPAC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cystic fibrosis

Defining Citation: [PMID:1692630](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:12800145](#), [PMID:14695172](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15463957](#), [PMID:15688027](#), [PMID:16912165](#), [PMID:18380791](#), [PMID:19077451](#), [PMID:20164919](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CFPAC-1

Synonyms: CFPac-1, CF PAC-1, CF-PAC1, CF-Pac1, CF Pac1, CFPAC1, CFPac1, CFPAC

Cross References: BTO:BTO_0004738, CLO:CLO_0002395, EFO:EFO_0006551, CLDB:cl705, CLDB:cl7121, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1918, BioGRID_ORCS_Cell_line:439, BioSample:SAMN03471976, BioSample:SAMN10987887, cancercellines:CVCL_1119, CCRID:1101HUM-PUMC000245, CCRID:3101HUMTCHu112, CCRID:4201HUM-CCTCC00249, CCTCC:GDC0249, Cell_Model_Passport:SIDM00130, CGH-DB:164-1, CGH-DB:9273-4, ChEMBL-Cells:ChEMBL3308032, ChEMBL-Targets:ChEMBL613506, CLS:305066, Cosmic:710854, Cosmic:868245, Cosmic:872998, Cosmic:906821, Cosmic:913305, Cosmic:922259, Cosmic:923168, Cosmic:932518, Cosmic:948375, Cosmic:948741, Cosmic:949322, Cosmic:1006363, Cosmic:1122343, Cosmic:1198207, Cosmic:1299298, Cosmic:1358477, Cosmic:1518233, Cosmic:1571776, Cosmic:2434110, Cosmic-CLP:906821, DepMap:ACH-000138, ECACC:91112501, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906821, GEO:GSM206454, GEO:GSM244428, GEO:GSM621903, GEO:GSM784694, GEO:GSM886925, GEO:GSM887991, GEO:GSM1024400, GEO:GSM1374446, GEO:GSM1374447, GEO:GSM1374448, GEO:GSM1669672, IARC_TP53:2839, ICLC:HTL01019, IZSLER:BS TCL 166, KCB:KCB 200730YJ, LiGeA:CCL_601, LINCS_LDP:LCL-1748, PharmacDB:CFPAC1_193_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL_1119, PubChem_Cell_line:CVCL_1119, SKY/M-FISH/CGH:1998, Wikidata:Q28199352

ID: CVCL_1119

Record Creation Time: 20220427T215450+0000

Record Last Update: 20260920T001753+0000

Ratings and Alerts

No rating or validation information has been found for CFPAC-1.

No alerts have been found for CFPAC-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 386 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou X, et al. (2026) DPP4 suppresses pancreatic cancer growth by enhancing ferroptosis sensitivity through stabilization of ACSL4. Cellular signalling, 143, 112446.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Shao H, et al. (2026) KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. *Science advances*, 12(8), eaea2511.

Qian Y, et al. (2026) Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. *Cell death & disease*, 17(1).

Wang X, et al. (2026) Mapping Genetic Regulation of Transcription to Identify Functional Variants and Genes Associated with Pancreatic Cancer Risk. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(29), e17184.

Cocc?? V, et al. (2026) Secretome From Human Micro-Fragmented Adipose Tissue Affects In Vitro Monocytes/Macrophages Inflammatory Activity by ICAM-1 Expression. *Mediators of inflammation*, 2026(1), e9475320.

Kong C, et al. (2026) Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. *Communications biology*, 9(1).

Zhang Y, et al. (2026) Integrative multi-omics analysis identifies ATAD1 as a potential regulator of metastasis in pancreatic cancer. *Scientific reports*, 16(1).

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. *iScience*, 29(6), 115978.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Li Z, et al. (2026) An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(24), e15606.

Zhu L, et al. (2026) The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway. *Drug design, development and therapy*, 20, 568551.

Tang R, et al. (2026) Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. *Cancer cell*.

Zhang S, et al. (2025) Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenocarcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e11726.

Song X, et al. (2025) Cytosolic cytochrome c represses ferroptosis. *Cell metabolism*, 37(6), 1326.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. *Cell reports*, 44(4), 115541.

Foot JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Petrenko O, et al. (2025) Intratumor heterogeneity in KRAS signaling shapes treatment resistance. *iScience*, 28(2), 111662.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. *Cancer letters*, 622, 217713.